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Abstract 
Background: Studies on a new coronavirus disease (COVID-19) show the elevation of liver enzymes and liver fibrosis 
index (FIB-4) independently on pre-existing liver diseases. It points to increased liver fibrogenesis during acute COVID-
19 with possible long-term consequences. This study aimed to assess liver fibrosis in COVID-19 patients by serum 
hyaluronic acid (HA) and FIB-4.
Methods: The study included the acute COVID-19 group (66 patients, 50% females, mean age 58.3 ± 14.6), the post-
COVID group (58 patients in 3–6 months after the recovery, 47% females, mean age 41.2 ± 13.4), and a control group 
(17 people, 47% females, mean age 42.8 ± 11.0). Ultrasound elastography was performed in the post-COVID and 
control groups.
Results: Sixty-five percent of the acute COVID-19 group had increased FIB-4 (> 1.45), and 38% of patients had 
FIB-4 ≥ 3.25. After matching by demographics, 52% of acute COVID-19 and 5% of the post-COVID group had 
FIB-4 > 1.45, and 29% and 2% of patients had FIB-4 ≥ 3.25, respectively. Increased serum HA (≥ 75 ng/ml) was 
observed in 54% of the acute COVID-19 and 15% of the post-COVID group. In the acute COVID-19 group, HA posi-
tively correlated with FIB-4, AST, ALT, LDH, IL-6, and ferritin and negatively with blood oxygen saturation. In the post-
COVID group, HA did not correlate with FIB-4, but it was positively associated with higher liver stiffness and ALT.
Conclusion: More than half of acute COVID-19 patients had increased serum HA and FIB-4 related to liver function 
tests, inflammatory markers, and blood oxygen saturation. It provides evidence for the induction of liver fibrosis by 
multiple factors during acute COVID-19. Findings also indicate possible liver fibrosis in about 5% of the post-COVID 
group.
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Introduction
The studies on a new coronavirus disease (COVID-19) 
frequently show impaired liver function with elevated 
transaminases. In some cases, the elevation of liver 
enzymes was more than three times and reflected a liver 
injury independently on pre-existing liver diseases [1]. 
Autopsies of COVID-19 patients with biochemical evi-
dence of hepatitis revealed macrovesicular steatosis, lob-
ular necroinflammation, and mild portal inflammation 
in most cases [2]. Possible hepatotropism of the SARS-
CoV-2 virus, systemic inflammatory response, hypoxic 
ischemia–reperfusion injury, and direct drug effect are 
the main reasons for impaired liver function and liver 
injury during COVID-19 [3, 4].
A liver biopsy can be very informative for the liver 
investigation at the time of the acute COVID-19 injury 
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[5]. At the same time, obtaining liver tissue during active 
respiratory illness is technically and clinically challenging 
[4], especially in the view of the possibility of COVID-19 
related coagulopathy [6, 7]. This most likely is a reason for 
only three biopsies performed in patients with COVID-
19 presented in publications [8, 9]. Using non-invasive 
tests in assessing processes in liver in the early stage of 
COVID-19 can extend our knowledge in the pathogen-
esis of SARS-CoV-2 infection and provide the basis for 
applying these markers for monitoring acute illness.
Liver fibrosis index (FIB-4) is one of these tests, which 
is widely used in detecting a stage of fibrosis and moni-
toring of chronic liver diseases, including chronic viral 
hepatitis, HIV/HCV co-infection, and metabolic-associ-
ated fatty liver disease [10, 11]. Recent studies in patients 
with COVID-19 [12–14] showed that more than half of 
patients at admission to the hospital had increased FIB-4. 
The level of FIB-4 is thought to be related to SARS-CoV-2 
viral load and levels of interleukin 6 (IL-6) and inter-
feron gamma-induced protein (IP-10) [15]. These studies 
underline that FIB-4 at the early stage of COVID-19 dis-
ease is a predictor of a negative outcome and the need for 
mechanical ventilation in middle-aged patients. However, 
some authors [12, 13] point that FIB-4 may not reflect 
liver fibrosis due to transient elevation of transaminases 
during acute COVID-19. Simultaneously, these studies 
did not assess an association of FIB-4 with other param-
eters of liver fibrosis as serum hyaluronic acid (HA) or 
liver stiffness, measured by ultrasound elastography. The 
analysis of these relationships can reveal possible liver 
fibrosis and its mechanisms in acute COVID-19.
HA is one of the oldest serum biomarkers of liver fibro-
sis, which was revealed by Meyer and Palme [16]. Pro-
duced by fibroblasts and specialized connective tissue 
cells, HA is a mucopolysaccharide forming an extracellu-
lar matrix. In a healthy human, serum HA ranges from 0 
to 75 ng/ml [17]. Hepatic stellate cells (HSC) are respon-
sible for HA synthesis in the liver. Pro-inflammatory 
cytokines transform HSC into myofibroblasts, producing 
more HA than non-activated HSC [18]. The association 
between increased serum HA and a stage of liver fibrosis, 
described in chronic viral hepatitis B or C and HIV/HCV 
co-infection [11, 19–21], showed that serum HA is a use-
ful marker of fibrogenesis. The enhanced production of 
HA in response to various viral, toxic, and inflammatory 
stimuli can reflect fibrotic processes in other tissue (for 
example, in the lungs). A previous study on COVID-19 
[22] detected serum HA in association with the lung 
damage. However, currently there are no data on the 
association of HA with hepatic impairment in COVID-19 
patients.
The assessment of the health status of people 
after COVID-19 is the additional issue of our study. 
COVID-19-associated hepatocellular and cholangiocel-
lular injury may lead to activation of HSC and induction 
of fibrosis, which can cause long-term consequences [1].
Our study aimed to assess liver fibrosis in COVID-19 
patients by serum HA and FIB-4 and to detect their rela-
tionship with liver function tests, inflammatory markers, 
and blood oxygen saturation. Possible liver fibrosis was 
assessed upon admission to the hospital and 3–6 months 
after the recovery (post-COVID). Additionally, in the 
post-COVID group, the measurements of HA and FIB-4 
were combined with ultrasound elastography findings. 
The latter reflects the physical properties of the liver and 
is a validated non-invasive method for detecting and 
staging liver fibrosis [23, 24]. Unfortunately, the assess-
ment of liver stiffness in the acute COVID-19 was not 
possible due to safety protocol limitations.
Material and methods
Participants
The study was conducted from September to Decem-
ber 2020. The Central Medical Ethics Committee, Riga, 
Latvia (protocol No. 01-29.1/2429), and the Ethics Com-
mittee of Rīga Stradiņš University, Latvia (protocol No. 
6-1/07/14) provided approval for the study. All par-
ticipants signed the informed consent form. The study 
was performed in accordance with the Declaration of 
Helsinki.
The cross-sectional, single-center study included 141 
participants, divided into three groups: 66 patients with 
acute COVID-19 (acute COVID-19 group), 58 patients 
3–6 months after acute COVID-19 (post-COVID group), 
and 17 participants without COVID-19 (control group). 
All patients with acute COVID-19 were treated in Riga 
East Clinical university hospital.
The diagnosis of SARS-CoV-2 infection was confirmed 
by positive real-time reverse-transcription polymerase 
chain reaction (RT-PCR) for SARS-CoV-2 nucleic acids 
in a nasopharyngeal swab. All participants in the con-
trol group had negative SARS-CoV-2 nucleic acids and 
negative anti-SARS-CoV-2 antibodies tests at the time of 
health status assessment. Data on the presence of comor-
bidities were obtained from medical documentation and 
by a survey.
Clinical tests
The clinical tests included: white cells count (WBC), 
erythrocytes (RBC), platelet count (PLT), absolute  CD4+ 
T lymphocyte count, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), ferritin, interleukin 6 
(IL-6), alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), lactate dehydrogenase (LDH), and 
creatinine. In acute patients, blood samples were received 
within 24  h of admission to the hospital. Data of blood 
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oxygen saturation  (SpO2) at admission to the hospital 
and the minimal level of  SpO2 during hospitalization also 
were analyzed.
Hyaluronic acid
Venous blood samples were centrifuged at 4000×g for 
10  min, and serum was stored at − 80  °C until analysis. 
For acute patients, serum samples were obtained within 
24 h after admission to the hospital. For all participants, 
serum samples were obtained on an empty stomach. 
Hyaluronic acid (HA) was detected by an enzyme-linked 
immunosorbent assay kit (Hyaluronan Quantikine 
ELISA Kit, R&D Systems, USA) following manufacturer 
instruction.
Index of liver fibrosis (FIB‑4)
To assess the level of liver fibrosis, FIB-4 was calculated 
[10]:
The levels of FIB-4 were categorized according to vali-
dated cut-off levels [10]: FIB-4 < 1.45 (negative predictive 
of advanced liver fibrosis), FIB-4 = 1.45–3.24 (significant 
liver fibrosis), and FIB-4 ≥ 3.25 (advanced liver fibrosis).
Ultrasound elastography
The ultrasound examination included 2D-shear wave 
elastography (2D-SWE) for quantitative analysis of fibro-
sis because pathologically increased liver stiffness in 
kPa correlates to decreased tissue elasticity. In addition, 
shear wave dispersion pattern (SWD) in (m/s)/kHz was 
used as an indicator of tissue viscosity and suggestive of 
inflammation [25]. The quantitative evaluation of both 
parameters was performed in a selected homogenous 
area of the liver parenchyma with at least five consequent 
measurements taken to obtain median values. Measure-
ments were considered reliable if the interquartile range/
median ratio (IQR/M) was lower than 0.3. Due to safety 
and availability concerns, SWE and SWD measurements 
were not performed for patients in the acute COVID-19.
Statistics
The biomarker levels were presented as median values 
and interquartile range. The Kruskal–Wallis test was 
applied for a comparison of independent groups. Multi-
ple pairwise comparisons used the Dunn-Bonferroni sig-
nificance correction. The Wilcoxon test was used for the 
assessment of dynamics within a group. The relationships 
between variables were assessed by the Spearman rank 
correlation coefficient. All computations were performed 






{PLT (×103/µl)× [ALT (U/l)]1/2}.
Results
Demographics and clinical characteristic of groups
The acute COVID-19 group included 66 patients 
(50% females) aged between 26 and 82 (mean age was 
58.3 ± 14.6). Unilateral pneumonia was diagnosed in 
18%, and bilateral pneumonia in 70% of patients. Other 
patients in the acute COVID-19 group (12%) did not 
have radiologically confirmed pneumonia. Blood oxygen 
saturation ≤ 93% was observed in 62% of patients dur-
ing the hospitalization period. COVID-19 progression 
to the acute respiratory distress syndrome (ARDS) was 
observed in two patients. Ten percent of patients were 
treated in the Intensive Care Unit, and two patients (3%) 
died. Comorbidities were presented in 65% of the acute 
COVID-19 group: 50% of patients had hypertension, 
9%—chronic heart failure, 17%—diabetes, 8%—asthma, 
and 2%—pulmonary fibrosis. Chronic liver disease was 
reported in 6% of patients (one patient had fatty liver dis-
ease while three patients had chronic viral hepatitis B or 
C).
The post-COVID group included 58 patients (47% 
females) aged between 20 and 66 (mean age was 
42.1 ± 13.4). Hypertension was present in 6% of patients, 
asthma in 5%, and 3% of patients had chronic liver dis-
ease (one patient had fatty liver disease, and one patient 
had chronic viral hepatitis C).
The control group included 17 people (47% females) 
aged between 26 and 63 (mean age was 42.8 ± 11.0). 
Between comorbidities, hypertension was present in 
6% and asthma in 12% of the control group. There were 
no participants with a previous history of chronic liver 
disease.
Clinical indicators in acute COVID‑19 patients
Table 1 presents the clinical tests of patients upon admis-
sion to the hospital in the acute COVID-19 group. The 
analysis revealed changes in liver function in acute 
patients before starting any specific COVID-19 therapy. 
Acute COVID-19 patients had abnormal transaminases 
at admission to the hospital, 29% and 38% for ALT and 
AST, respectively. FIB-4 at the level 1.46–3.24 was pre-
sented in 27% of acute patients, and FIB-4 ≥ 3.25 was 
in 38% of patients. The normal FIB-4 index (< 1.45) was 
identified in a third of patients. A half of patients (54%) 
had abnormal HA levels (cut-off for HA ≥ 75 ng/ml).
In the acute COVID-19 group, the medians of LDH, 
CRP, ferritin, IL-6, and ESR at admission to the hospital 
were higher than the upper limit of a reference inter-
val. Forty-two percent of acute patients at admission 
had  CD4+ T lymphocyte count lower than 400 cells/
mm3. A third of patients at admission had oxygen satu-
ration ≤ 93%. The median levels of blood cells and cre-
atinine in acute patients were in the reference interval.
Page 4 of 9Kolesova et al. BMC Gastroenterol          (2021) 21:370 
The correlation analysis revealed relationships 
between markers of liver fibrosis, liver ferments, 
inflammatory markers, and oxygen saturation in the 
acute COVID-19 group (Table 2).
In the acute COVID-19 group, HA correlated with all 
parameters except for CRP. HA was higher in patients 
with higher AST  (rs = 0.52, p < 0.001), ALT  (rs = 0.39, 
p = 0.001), FIB-4  (rs = 0.50, p < 0.001), LDH  (rs = 0.52, 
p < 0.001), IL-6  (rs = 0.35, p = 0.009), ferritin  (rs = 0.31, 
p = 0.012), and lower oxygen saturation at admission 
 (rs = − 0.49, p < 0.001).
FIB-4 correlated also with AST  (rs = 0.60, p < 0.001), 
LDH  (rs = 0.41, p < 0.001), ferritin  (rs = 0.30, p < 0.05), and 
IL-6  (rs = 0.41, p < 0.01). Oxygen saturation at admission 
to the hospital negatively correlated with all parameters 
except for FIB-4.
Differences between groups
Considering the revealed correlation between age and 
FIB-4 and HA level, we compared all the parameters in 
three groups matched by demographics. The age of acute 
patients was adjusted to other groups.
FIB-4, HA, AST, LDH, CRP, ferritin, IL-6, and ESR 
at admission to the hospitals (acute COVID-19 group) 
were higher than in the post-COVID and the control 
groups (Table  3). Adjusted estimates of the effect size 
(eta-square) for nonparametric comparisons [26] and 
an approximate estimate of the statistical power [27] for 
each marker indicated that effect sizes for FIB-4, LDH, 
CRP, IL-6, and ESR were no less than 0.14 or large [26] 
and provided sufficient statistical power (> 0.80). Effect 
sizes for AST and ferritin also were large, while the effect 
Table 1 Baseline clinical indicators in the acute COVID-19 group (n = 66)
IQR, interquartile range; HA, hyaluronic acid; WBC, leucocytes; RBC, erythrocytes; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; LDH, lactate dehydrogenase; IL-6, interleukin 6; ESR, erythrocytes sedimentation rate;  SpO2, oxygen saturation in blood
Parameters Median (IQR) Missing data, n
Indicators of fibrosis
 FIB-4 (IQR) 2.51 (1.30; 3.56) –
  FIB-4 ≤ 1.45 35%
  FIB-4 1.46–3.24 27%
  FIB-4 ≥ 3.25 38%
 HA, ng/ml (IQR) 80.75 (45.94; 157.62) –
  HA ≥ 75 ng/ml 54%
Enzymes
 ALT, U/l (IQR) 27 (18; 43) –
  ALT > 40 U/l 29%
 AST, U/l (IQR) 35 (22; 50) –
  AST > 40 U/l 38%
 LDH, U/l (IQR) (reference range 135–225) 288 (213; 416) 4
Blood cells
 WBC, ×  103/µl (IQR) (reference range 4.0–9.0) 5.12 (4.19; 6.84) –
 RBC, ×  106/µl (IQR) (reference range: males 4.0–5.5, females 3.9–5.0) 4.58 (4.22; 4.90) –
 Platelet, ×  103/µl (IQR) (reference range150–400) 185 (143; 229) –
  CD4+ T lymphocytes, cells/mm3 (IQR) 471 (312; 646) 16
   CD4+  < 400 cells/mm3 42%
Inflammatory markers
 CRP, mg/l (IQR) (reference range < 5.0) 41.82 (12.34; 86.98) –
 Ferritin, ng/ml (IQR) (reference range 30–400) 365.6 (171.3; 900.6) 1
 IL-6, pg/ml (IQR) (reference range < 5.0) 16.10 (8.15; 44.50) 13
 ESR, mm/h (IQR) (reference range < 20) 27.0 (18.0; 40.8) 2
Renal function
 Creatinine, µmol/l (IQR) (reference range: male 62–106, female 44–80) 75 (65; 93) 2
Oxygen saturation
  SpO2 at admission, % 95 (91; 98) 9
  SpO2 ≤ 93% at admission 30%
 Lowest  SpO2 during hospitalization 92 (88; 95) 3
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size for HA was medium. However, these three findings 
demonstrated lowered statistical power.
Platelets and  CD4+ T lymphocyte count were lower 
in the acute COVID-19 group than in the post-COVID 
and the control groups. Both comparisons revealed large 
effect sizes, but the statistical power was lowered for 
platelets and sufficient for  CD4+ T lymphocyte count. 
Moreover,  CD4+ T lymphocyte count < 400 cells/mm3 
was observed in 24% of the COVID-19 group and 5% 
of the post-COVID group. ALT, WBC, and creatinine 
had no differences between groups. In the post-COVID 
group, the patients had higher erythrocyte count than in 
the control and acute COVID-19 groups.
Assessment of liver fibrosis showed that the patients 
with acute COVID-19 had a higher FIB-4 than in post-
COVID and control groups. Intermediate liver fibrosis 
index (FIB-4 = 1.46–3.24) was observed in 19% of acute 
patients, in 3% of post-COVID, and 6% of the control 
group. At the same time, FIB-4 ≥ 3.25 was identified in 
29% of acute and only in 2% of post-COVID patients. In 
the control group, a high level of liver fibrosis was not 
observed.
A similar tendency was observed in HA measure-
ments. Patients with acute COVID-19 had a higher HA 
level than participants in post-COVID and the control 
groups. The level of HA ≥ 75  ng/ml was observed in 
32% of acute COVID-19 patients, in 15% of the post-
COVID group. In the control group, a high HA level 
was not observed.
It should be noted that two patients in the post-
COVID group were with chronic liver diseases in the 
anamnesis. However, their FIB-4 levels (0.84 and 1.26) 
and HA (74.56 and 69.10 ng/ml) were not elevated.
Dynamics in a small group
Ten patients of the post-COVID group presented with 
some blood parameters at two temporal points: at 
admission to the hospital and after 3–6  months after 
recovery (Table  4). It should be noted that a small 
group of patients provided a provisory assessment of 
change and estimates of the effect size.
The longitudinal investigation of these patients 
showed that inflammatory markers (ESR, CRP) and 
FIB-4 were higher in the acute COVID-19 than in the 
post-COVID period. Erythrocytes were higher in the 
post-COVID than in the acute COVID-19. Leucocyte 
count, ALT, and creatinine did not show differences 
between the two measurements. AST and platelets 
showed marginal differences (p = 0.052 and p = 0.051, 
respectively) with higher AST and lower PLT in acute 
COVID-19 than in the post-COVID period. Consider-
ing both parameters are included in the FIB-4 index, 
these marginal tendencies added to higher FIB-4 in 
acute COVID than after recovery.
Ultrasound elastography for the post‑COVID and control 
groups
There were no differences between the post-COVID and 
control groups in the measurements of SWE, z = − 0.08, 
p = 0.937, and SWD, z = −  0.72, p = 0.474. SWE was 
4.60 kPa (IQR: 4.00; 5.53) in the post-COVID group and 
Table 2 Spearmen rank correlation coefficients in the acute COVID-19 group
HA, hyaluronic acid; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C-reactive protein; IL-6, interleukin 6;  SpO2, 
blood oxygen saturation. ***p < 0.001; **p < 0.01; *p < 0.05
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4.55 kPa (IQR: 4.15; 4.88) in the control group. SWD was 
11.75 (m/s)/kHz (IQR: 10.53; 12.75) and 12.10 (m/s)/
kHz (IQR: 11.23; 13.20) in the post-COVID and the con-
trol groups, respectively. At the same time, SWE corre-
lated with HA  (rs = 0.30, p = 0.021) and ALT  (rs = 0.32, 
p = 0.013), while the correlation with FIB-4 was not sig-
nificant  (rs = 0.15, p = 0.26) in the post-COVID group. 
There were no significant correlations between elastogra-
phy data and FIB-4 and HA in the control group.
Table 3 Baseline clinical indicators in independent groups matched by demographics
Different superscripts indicate significant differences between subgroups. IQR, interquartile range; HA, hyaluronic acid; WBC, leucocytes; RBC, erythrocytes; CRP, 
C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; IL-6, interleukin 6; ESR, erythrocytes sedimentation 
rate; η2, estimate of the effect size for the Kruskal–Wallis test. Missing data reduced the number of measures in the COVID-19 group in LDH (n = 28),  CD4+ (n = 21), IL-6 
(n = 26), and ESR (n = 29)
Parameters Patients group Kruskal–Wallis, p 
value
η2
COVID‑19 (n = 31) Post‑COVID (n = 58) Control (n = 17)
Demographics











 Females 48% 47% 47%
Indicators of fibrosis
 FIB-4 (IQR) 1.45a (0.85; 3.31) 0.59b (0.45; 0.77) 0.62b (0.54; 1.01) 30.17
p < 0.001
0.28
 FIB-4 ≤ 1.45 52% 95% 94%
 FIB-4 1.46–3.24 19% 3% 6%
 FIB-4 ≥ 3.25 29% 2% 0%
 HA, ng/ml (IQR) 51.80a (31.84; 81.50) 35.95b (15.93; 70.18) 26.30b (16.35; 34.80) 11.91
p = 0.003
0.10
 HA ≥ 75 ng/ml 32% 15% 0%
Enzymes
 ALT, U/l (IQR) 26 (14; 46) 26 (20; 36) 24 (20; 33) 3.58
p = 0.167
0.02
 AST, U/l (IQR) 30a (21; 42) 19b (17; 24) 20b (18; 28) 16.28
p < 0.001
0.14




 WBC, ×  103/µl (IQR) 5.10 (4.19; 6.99) 5.55 (4.73; 6.44) 6.48 (5.26; 7.52) 3.58
p = 0.167
0.02
 RBC, ×  106/µl (IQR) 4.46a (4.21; 5.02) 4.87b (4.59; 5.15) 4.63ab (4.30; 5.20) 7.01
p = 0.030
0.05
 Platelet, ×  103/µl (IQR) 183a (144; 212) 248b (200; 271) 251b (213; 294) 16.55
p < 0.001
0.14
  CD4+ T lymphocytes, cells/
mm3 (IQR)
479a (401; 682) 830b (665; 1035) 860b (710; 1020) 20.14
p < 0.001
0.18
  CD4+  < 400 cells/mm3 24% 5% 0%
Inflammatory markers
 CRP, mg/l (IQR) 28.00a (5.90; 68.80) 0.65b (0.31; 1.77) 0.60ab (0.31; 2.08) 49.00
p < 0.001
0.46
 Ferritin, ng/ml (IQR) 291.7a (142.8; 918.1) 108.5b (72.8; 165.3) 108.0b (47.9; 304.5) 16.79
p < 0.001
0.15
 IL-6, pg/ml (IQR) 11.18a (5.07; 28.08) 3.45b (2.35; 4.90) 3.5b (2.0; 4.3) 35.55
p < 0.001
0.33




 Creatinine, µmol/l (IQR) 76 (65; 87) 71 (65; 78) 74 (63; 85) 1.39
p = 0.498
0.01
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Discussion
Our findings indicated a high percentage of patients with 
impaired liver function and increased markers of liver 
fibrosis in acute COVID-19. Intercorrelations among 
most of the parameters under investigation pointed at 
the multifactorial liver injury. Longitudinal data in a 
small group showed liver function restoration after the 
recovery. However, about 5% of patients in the post-
COVID group had signs of liver fibrosis independently of 
pre-existing liver diseases, and they should be monitored 
for a longer time.
FIB‑4 level at baseline and its association with other 
parameters
Using the cut-off levels of FIB-4 [10] revealed a high 
percentage of COVID-19 patients (65%) with abnormal 
liver fibrosis index (FIB-4 > 1.45). Interpretation of FIB-4 
levels showed that 38% of patients had advanced liver 
fibrosis (FIB-4 ≥ 3.25) at admission, and 27% of patients 
had an intermediate level of FIB-4 (1.46–3.24). Analysis 
of differences between patients with acute COVID-19, 
after recovery, and the control group matched by demo-
graphics also showed a higher percentage of patients 
(52%) with FIB-4 > 1.45 in acute COVID-19 than in post-
COVID groups (5%) and in the control group (6%). It is 
necessary to note that 29% of acute COVID-19 and 2% 
of post-COVID groups had dramatically increased FIB-4 
(≥ 3.25). This FIB-4 level was not presented in the control 
group.
Similar findings in FIB-4 were described in Ibáñez-
Samaniego et  al. [12] and Sterling et  al. [13] studies, 
revealing abnormal FIB-4 in 76% of acute patients at 
baseline [12] and FIB-4 > 3.25 in 42% of patients [13]. 
On the one hand, increased FIB-4 can reflect underdi-
agnosed pre-existing chronic liver disease [12, 13, 15]. In 
our study, pre-existing liver disease were reported only 
in 6% of acute COVID-19 patients, similarly to Sterling 
et  al. [13]. On the other hand, FIB-4 in acute COVID-
19 can reflect systemic inflammation because of posi-
tive correlations with IL-6 and IP-10 [15]. In our study, a 
higher FIB-4 was observed in acute patients with a higher 
level of AST, LDH, IL-6, and ferritin that is in line with Li 
et al. [15]. Moreover, we can conclude that FIB-4 reflects 
COVID-19 severity associated with hepatocellular dam-
age (increased AST), systemic inflammation (increased 
IL-6 and ferritin), and lung damage (increased LDH), 
observed during acute SARS-CoV-2 infection [28].
The dynamics of FIB-4 in COVID-19 were also ana-
lyzed in previous studies [12, 15]. Li et  al. [15] showed 
that, during hospitalization, FIB-4 peaked and then 
normalized in the survival group but failed to normal-
ize in the death group. Ibáñez-Samaniego et al. [12] ana-
lyzed FIB-4 values in a small group of patients 6 months 
before the diagnosis of COVID-19 and upon admission 
to the hospital and observed that FIB-4 categories did not 
change between the time points. In our study, we have 
investigated the level of FIB-4 at admission to the hos-
pital and in 3–6 months after the recovery. In the small 
group of patients, we have revealed a decrease of FIB-4 
after discharging from the hospital. It concurs with Li 
et  al. [15]. Moreover, these results confirm the relation-
ship between FIB-4 and the level of inflammation.
Serum HA and its association with other parameters
The analysis of serum HA revealed that half of 
the patients at admission to the hospital had HA 
level ≥ 75  ng/ml. It was higher in patients with higher 
FIB-4, AST, ALT, LDH, IL-6, and ferritin and lower oxy-
gen saturation at admission that indicated the multi-
factorial determination of an increase of HA in serum, 
including hepatocellular damage, hypoxia, and inflam-
mation. After matching by demographics, a higher HA 
level was also observed in the acute COVID-19 group 
than in the post-COVID group. Increased serum HA and 
Table 4 Dynamics of clinical tests in patients with COVID-19 at two-time points (n = 10)
IQR, interquartile range; WBC, leucocytes; RBC, erythrocytes; PLT, platelets; ESR, erythrocytes sedimentation rate; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; CRP, C-reactive protein; η2, estimate of the effect size for the Wilcoxon signed-rank test
Parameters Acute COVID‑19 (baseline) Post‑COVID z p η2
WBC, ×  103/µl (IQR) 5.39 (4.21; 6.95) 4.86 (4.63; 6.70) − 0.56 0.575 0.03
RBC, ×  106/µl (IQR) 4.47 (4.35; 4.74) 4.69 (4.57; 4.89) − 2.30 0.022 0.53
PLT, ×  103/µl (IQR) 205 (162; 245) 260 (230; 285) − 1.96 0.051 0.38
ESR, mm/h 19 (12; 43) 2 (2; 5) − 2.37 0.018 0.56
ALT, U/l (IQR) 21 (12; 47) 25 (16; 35) − 0.05 0.959 0.00
AST, U/l (IQR) 23 (20; 42) 19 (16; 26) − 1.94 0.052 0.38
FIB-4 (IQR) 0.99 (0.74; 3.11) 0.65 (0.45; 0.89) − 2.19 0.028 0.48
CRP, mg/l (IQR) 30.64 (3.30; 56.89) 1.92 (1.03; 5.44) − 2.70 0.007 0.73
Creatinine, µmol/l (IQR) 79 (57; 91) 73 (63; 82) − 0.42 0.678 0.02
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its association with the course of COVID-19 and poor 
prognosis previously was shown in another study [22]. In 
addition to these findings, Ding et  al. [22] described an 
increased level of procollagen type III and IV and laminin 
in patients with COVID-19, which may lead to the pos-
sible development of pulmonary fibrosis.
Increased serum HA during COVID-19 can be associated 
with the possible development of ARDS [29, 30]. The SARS-
CoV-2 virus directly infects alveolar epithelial cells and 
induces the increase of pro-inflammatory cytokines in the 
lung tissue. These cytokines are responsible for the increased 
production of HA by fibroblasts, which lead to the accu-
mulation of HA in alveolar space, development of hyaline 
membranes, and ARDS [30]. In our study, only two acute 
COVID-19 patients had ARDS. Therefore, we can conclude 
that revealed relationships between HA and FIB-4 and liver 
enzymes point to increased fibrogenesis in the liver.
Liver fibrosis is a wound-healing process in response to 
acute or chronic liver injury with increasing deposition of 
extracellular matrix and decreasing its degradation [18, 
31]. Association between HA and FIB-4, observed in the 
acute COVID-19 group, and relationships between HA 
and the stage of liver fibrosis [19, 31, 32] lead to a conclu-
sion that high HA and FIB-4 during COVID-19 can be 
related to increased liver fibrogenesis. Moreover, the level 
of liver fibrogenesis is associated with the level of hepa-
tocellular damage, inflammation, and hypoxia, described 
as possible mechanisms of liver injury and fibrosis in the 
acute COVID-19 [1, 3].
Assessing COVID‑19 consequences
In the post-COVID group 5% of patients had increased 
FIB-4, and 2% of them had advanced liver fibrosis 
(FIB-4 ≥ 3.25) despite the normal range of inflammatory 
markers. Similarly, serum HA > 75  ng/ml was observed 
in 15% of post-COVID patients. The analysis also dem-
onstrated that increased FIB-4 and HA levels in the 
post-COVID group were observed independently of pre-
existing liver diseases in anamnesis.
Data of ultrasound elastography provided additional 
information regarding the physical properties of liver 
parenchyma in the post-COVID group. Based on previous 
data [23, 24], liver stiffness measurements reflect the pres-
ence of liver fibrosis. Therefore, the association between 
a higher level of HA and higher SWE values confirms the 
increased liver fibrogenesis in the post-COVID group.
Liver disease in the anamnesis of two patients from 
the post-COVID group demonstrated no visible effect 
on the level of HA, FIB-4, SWE, and SWD. Therefore, 
the observed elevation of FIB-4 in 5% of patients in that 
group can be associated with consequences of COVID-
19 or previously underdiagnosed liver diseases. As a 
result, there is a need for further exploration of recovery 
after COVID-19. Simultaneously, a practical suggestion is 
a greater focus of the national healthcare system on early 
diagnostics and prevention.
Limitations
The study has visible limitations. First, the sample size 
was limited by the number of recovered patients dur-
ing the project. The temporal interval of 3–6  months 
was reached in a small number of patients because of 
a relatively favorable epidemiological situation in the 
country. The number of acute patients also is relatively 
small because of the absence of or fragmented data at 
admission to the hospital. An additional problem was 
limited information regarding pre-existing chronic liver 
diseases. Second, the size of the control group and the 
number of longitudinally investigated patients were also 
limited. Extending samples and involving new patients 
was limited by a strict time frame of the project and 
redirecting financial resources to coping with epidemio-
logical threats and challenges.
Conclusions
More than half of acute COVID-19 patients had 
increased serum HA and liver fibrosis index FIB-4 upon 
admission to the hospital independently to pre-existing 
chronic liver disease and development of ARDS. More-
over, in acute COVID-19 patients, serum HA is related 
to FIB-4, liver function tests, inflammatory markers, 
and blood oxygen saturation. It suggests impaired liver 
function and increased liver fibrogenesis in the acute 
COVID-19, determined by hypoxia and inflammation. 
In most patients, the liver injury is transitory. However, 
a follow-up (after 3–6 months) revealed signs of devel-
opment of liver fibrosis in some individuals. Further 
studies should focus on factors predisposed to COVID-
related consequences for liver functioning.
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